Protagonist Therapeutics has announced a new, highly potent oral triple agonist peptide development candidate for obesity.  

With once-daily dosing, PN-477o targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors. 

The company has announced it will also develop a subcutaneous version, PN-477sc, as a once-weekly injection. 

PN-477 is designed to offer a combination of total body weight loss, improved gastrointestinal (GI) tolerability and fat to lean mass ratio. 

Dr Dinesh Patel, President and CEO of Protagonist, commented: “PN-477 is specifically engineered to be orally stable with attention to the relative balance of potencies against the three receptors to potentially leverage their beneficial effects on weight loss and optimal body composition while mitigating their adverse effects.” 

PN-477 has completed extensive preclinical evaluation including oral and metabolic stability, potency, pharmacokinetics and pharmacodynamics studies, and has demonstrated effects in preclinical models of obesity and glycaemic control. 

It has also demonstrated robust preclinical proof-of-concept in various animal studies including 50% weight loss in the diet induced obesity (DIO) preclinical mouse model, and favourable results versus retatrutide in normal dogs and cynomolgus monkeys.  

IND enabling studies of PN-477 are underway and initiation of Phase I clinical studies is anticipated in the second quarter of 2026. 

“While GLP-1 agonists have dominated the market thus far, there remains a broad opportunity for novel therapeutics with better body weight loss, higher ratio of fat to lean mass loss, tolerability and additional beneficial effects in obesity-related comorbidities. A triple GLP-1, GIP, GCG receptor agonist peptide that offers weight loss on par with the best injectable treatments options, as well as the optionality provided by both oral and injectable routes of administration, would be an important therapeutic breakthrough and represents another potential blockbuster drug opportunity for Protagonist,” added Dr Patel.

Diana Turner, Senior Digital Content Editor, DDW